article thumbnail

How to Develop a Sustainable Generic Drug Development Strategy

Drug Patent Watch

The pharmaceutical industry, particularly the generic drug sector, faces significant challenges in adopting sustainable practices. Future Directions and Strategies By 2030, generics manufacturers will need to shift from the status quo and explore new avenues for change. Generics 2030: Three Strategies to Curb the Downward Spiral.

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3

article thumbnail

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Drug Channels

Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S. healthcare spending. Click here to see the original post from April 2022. spending on healthcare.

article thumbnail

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

Drug Channels

Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S. What’s more, taxpayers—via Medicare and Medicaid—will continue to crowd out the private insurance market. One bright spot: consumers will account for an ever-smaller share of drug spending. healthcare spending growth. to 1:30 p.m.

article thumbnail

Boosters and Biologics: Is Space-Based Biomanufacturing Real?

LifeSciVC

1,2,3 Among a long list of innovations, the lowest hanging fruit for commercialization is the use of microgravity-based crystallization to enhance high-value pharmaceuticals. Demand exceeds supply, and there is little hope in clearing the queue many ongoing studies wont even finish prior to the ISSs 2030 retirement.

Science 96
article thumbnail

Boehringer Ingelheim shares updated 2030 environmental sustainability commitments

The Pharma Data

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s impact on health, society, and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals. Boehringer Ingelheim’s commitment to MORE GREEN is underscored by a series of initiatives.